[Doping: epidemiological studies].
BACKGROUND
Whatever method is used (observation, interviews, questionnaire, laboratory tests), it is difficult to collect epidemiological data on doping. Particularly difficult problems are related to the definitions of sports players and the drugs involved as well as the often illicit nature of drug use.


RESULTS
The prevalence of doping in children and adolescents participating in sports is estimated at 3% to 5% with higher percentages in boys, older adolescents and those playing at a competition level. Use of anabolic steroids, as early as 8 years of age, has increased since 1990, especially in girls. All studies have emphasized how easy it is for adolescents to procure any prohibited drug. In adults participating in amateur sports, the prevalence of doping would be 5% to 15%. All sports are involved with higher prevalence in men, age ranges 20-25 years and 35-39 years, and competitive level players. The main drugs used are stimulants, narcotics, corticosteroids and anabolic steroids. Combination of at least 2 drugs is frequent with an increase of mean daily dose over the last 15 years. According to users, the drugs are obtained with a medical prescription, on the underground market, or from other participants. Few data are available on doping outside sports activities. In the French department Meurthe-et-Moselle, 15% of the inhabitants use drugs to improve their occupational performance.


CONCLUSIONS
Doping is more widespread than would be expected from antidoping control data. Other studies are needed to acquire more precise epidemiological data.
patrick.laure@wanadoo.fr
P
P
Laure
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D045930:Anabolic Agents / Q000009:adverse effects / Q000600:supply & distribution; D002648:Child; D003430:Cross-Sectional Studies; D004300:Doping in Sports / Q000331:legislation & jurisprudence / Q000517:prevention & control / Q000706:statistics & numerical data*; D005260:Female; D005602:France / Q000453:epidemiology; D006306:Health Surveys; D006801:Humans; D013287:Illicit Drugs / Q000009:adverse effects / Q000600:supply & distribution; D015994:Incidence; D008297:Male
D045930:Anabolic Agents; D013287:Illicit Drugs